REFERENCES
- Archer D. F., Furst K., Tipping D., Dain M. P., Vanepol C. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause (CombiPatch study group). Obstet. Gynecol. 1999; 94(4)498–503
- Chien Y. W., Chien T., Bagdon R. E., Huang Y. C., Bierman R. H. Transdermal dual-controlled delivery of contraceptive drugs: formulation development, in vitro and in vivo evaluations, and clinical performance. Pharmaceut. Res. 1989; 6(12)1000–1010
- Fotherby K. Levonorgestrel clinical pharmacokinetics. Clin. Pharmacokin 1995; 28(3)203–215
- Harrison L. I., Harari D. An evaluation of bioequivalence of two 7-day 17β-estradiol transdermal delivery systems by anatomical site. J. Clin. Pharmacol. 2002; 42(10)1134–1141
- Harrison L. I., Riedel D. J., Chang S. F., Jacobson J. P., Sellers J. A., Kanniainen C. M., Crowley J. K., Hinderling P. H. Comparative serum estradiol profiles from a new once-a-week transdermal estradiol patch and a twice-a-week transdermal estradiol patch. Ther. Drug Monit. 1997; 19(1)37–42
- Harrison L. I., Riedel D. J., Reynolds S. J., Kolars C. A., Chang S. F., Edgren A. R., Nelson J. R. Serum estradiol and estrone levels during 3 weeks of alternate-site and same-site applications of a once-a-week drug-in-adhesive transdermal estradiol patch. Am. J. Therap 1996; 3(8)574–579
- Kuhnz W., Al-Yacoub G., Fuhrmeister A. Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a wash-out phase, the same dose during one treatment cycle. Contraception 1992; 46(5)443–454
- Lipp R. Selection and use of crystallization inhibitors for matrix-type transdermal drug-delivery systems containing sex steroids. J. Pharm. Pharmacol. 1998; 50(12)1343–1349
- Lipp R., Laurent H., Gunther C., Riedl J., Esperling P., Tauber U. Prodrugs of gestodene for matrix-type transdermal drug deliver systems. Pharm. Res. 1998; 15(9)1419–1424
- Funke A. P., Gunther C., Muller R. H., Lipp R. In vitro release and transdermal fluxes of a highly lipophilic drug and of enhancers from matrix TDS. J. Contr. Release 2002; 82(1)63–70
- Pentikis H. S., Mullin M. E., Howard M., Boutouyrie B., Rhodes G. Evaluation of the bioavailability abd dose proportionality of three formulations of a combination estrogen and progestin adhesive-based matrix transdermal delivery system. Curr. Therap. Res. 1998; 59(10)681–691
- Schulman L. P., Yankov V., Uhl K. Safety and efficacy of a continuous once-a-week 17[beta]-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause 2002; 9(3)195–207
- Sicat B. L. Ortho Evra: a new contraceptive patch. Pharmacother. 2003; 23(4)472–480
- Shulman L. P. 17β-estradiol/levonorgestrel transdermal system for the management of the symptomatic menopausal woman. Expert Opin. Pharmacother. 2004; 5(12)2559–2566
- Thomas B. J., Finnin B. C. The transdermal revolution. Drug Discov. Today 2004; 15(16)697–703